|

Pucotenlimab Clinical Trials

10 actively recruiting trials

▲ +1 trial since August 2026

Also known as: HX008

Pipeline

Phase 2: 7Phase 1/2: 3

Top Sponsors

  • Sun Yat-sen University3
  • Zhejiang Provincial People's Hospital1
  • Tianjin Medical University Second Hospital1
  • Second Affiliated Hospital, Zhejiang University, School of Medicine1
  • Lepu Biopharma Co., Ltd.1

Indications

Other10 trials

Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck
Phase 2
EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer
Phase 2
Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen
Phase 1/2
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Phase 1/2
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Phase 2
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Phase 1/2
Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive
Phase 2
Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)
Phase 2
The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study
Phase 2
Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.